Drug Profile
Pratosartan
Alternative Names: DA 727; KD 3671; KT 3671Latest Information Update: 12 May 2015
Price :
$50
*
At a glance
- Originator Kotobuki Seiyaku
- Developer Boryung Pharmaceutical; Daiichi Sankyo Company; Kotobuki Pharmaceutical
- Class Antihypertensives; Imidazoles; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypertension
- Discontinued Atherosclerosis; Diabetic nephropathies; Glomerulonephritis
Most Recent Events
- 13 Apr 2012 Pratosartan is still in phase III development in South Korea and phase II in Japan for Hypertension
- 10 Sep 2010 Clinical development is ongoing in Japan and South Korea
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc